Biopharma companies raised $16.78 billion in public and private financings in January–February 2026, an 81% increase year‑over‑year, signaling renewed investor appetite for life‑science innovation. The data show a significant rebound from subdued 2022–2023 levels and reflect strong capital flows into peptides, oncology, and platform technologies. While the total still lags the outsized 2024 peak, the surge suggests greater risk tolerance among venture and crossover investors and a willingness to fund later‑stage clinical programs. Market participants will watch whether higher volumes sustain as regulatory clarity and clinical readouts play out.